Vericel Corp. (VCEL)
40.55
-0.34
(-0.83%)
USD |
NASDAQ |
Sep 03, 10:05
Vericel Research and Development Expense (TTM) : 29.17M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.17M |
| March 31, 2026 | 28.41M |
| December 31, 2025 | 27.56M |
| September 30, 2025 | 25.23M |
| June 30, 2025 | 25.01M |
| March 31, 2025 | 25.64M |
| December 31, 2024 | 24.80M |
| September 30, 2024 | 24.78M |
| June 30, 2024 | 24.36M |
| March 31, 2024 | 22.25M |
| December 31, 2023 | 21.04M |
| September 30, 2023 | 21.39M |
| June 30, 2023 | 20.76M |
| March 31, 2023 | 20.30M |
| December 31, 2022 | 19.94M |
| September 30, 2022 | 18.62M |
| June 30, 2022 | 17.86M |
| March 31, 2022 | 17.52M |
| December 31, 2021 | 16.29M |
| September 30, 2021 | 15.48M |
| June 30, 2021 | 14.11M |
| March 31, 2021 | 12.89M |
| December 31, 2020 | 13.02M |
| September 30, 2020 | 13.12M |
| June 30, 2020 | 13.30M |
| Date | Value |
|---|---|
| March 31, 2020 | 31.15M |
| December 31, 2019 | 30.39M |
| September 30, 2019 | 30.19M |
| June 30, 2019 | 30.21M |
| March 31, 2019 | 12.88M |
| December 31, 2018 | 13.60M |
| September 30, 2018 | 14.17M |
| June 30, 2018 | 13.97M |
| March 31, 2018 | 13.21M |
| December 31, 2017 | 12.94M |
| September 30, 2017 | 13.62M |
| June 30, 2017 | 14.14M |
| March 31, 2017 | 15.23M |
| December 31, 2016 | 15.30M |
| September 30, 2016 | 18.44M |
| June 30, 2016 | 18.74M |
| March 31, 2016 | 18.05M |
| December 31, 2015 | 18.89M |
| September 30, 2015 | 17.28M |
| June 30, 2015 | 21.38M |
| March 31, 2015 | 22.37M |
| December 31, 2014 | 21.26M |
| September 30, 2014 | 18.78M |
| June 30, 2014 | 13.52M |
| March 31, 2014 | 12.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| AbbVie, Inc. | 9.714B |
| ADMA Biologics, Inc. | 11.52M |
| Kyntra Bio, Inc. | 22.86M |
| Conexeu Sciences, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 331.01M |